<DOC>
	<DOCNO>NCT02623491</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , pharmacokinetics JNJ-55375515 healthy participant administration single multiple oral dos .</brief_summary>
	<brief_title>Study Investigate Safety , Tolerability , Pharmacokinetics JNJ-55375515 Healthy Participants</brief_title>
	<detailed_description>This randomize ( study medication assign participant chance ) , double-blind ( neither investigator participant know treatment participant receiving ) , placebo-controlled ( inactive comparator treatment study drug ) , single center study healthy male participant female participant non-childbearing potential ( surgically sterile post menopausal ) , age 18 58 year inclusive . This study consist two part ; Single Ascending Dose ( SAD ) part Multiple Ascending Dose ( MAD ) part . The SAD consist 6 escalate dose cohort . Participants cohort randomize receive single oral administration JNJ-55375515 placebo overnight fast . The planned dos JNJ-55375515 range 0.75 100 milligram ( mg ) . Participants additional cohort dose fed state determine effect food safety , tolerability pharmacokinetics JNJ-55375515 . An additional optional cohort may evaluate explore safety , tolerability , pharmacokinetics , pharmacodynamics JNJ-55375515 , maximal dose exceed 200 mg . The study duration participant SAD part study approximately 2 5.5 week , include eligibility Screening . The MAD consist 3 cohort 9 participant . Participants receive daily oral dos JNJ-55375515 placebo 10 consecutive day . The study duration participant MAD part study approximately 3 7 week include eligibility Screening . The Safety Participants monitor throughout study .</detailed_description>
	<criteria>Participant must healthy basis physical neurological examination , medical history , vital sign , electrocardiogram ( ECG ) , body mass index 1830 kilogram / square meter ( kg/m^2 ) body mass le 50 kg . Participant must healthy basis clinical laboratory test perform Screening Day 1 . Female participant must childbearing potential either postmenopausal permanently sterilize . Female participant must pregnant . Participant must willing able adhere prohibition restriction specify protocol , include contraception . Each participant must sign informed consent form ( ICF ) indicate understands purpose , procedure require , study willing participate study . Participant current , history , clinically significant medical psychiatric illness . Participant condition participation would best interest participant could prevent , limit , confound protocol specify assessment interpretation study result . Participant personal history , first degree relative history , acute angleclosure glaucoma , participant significant hyperopia ( farsightedness ) . Participant QT correct accord Fridericia 's formula ( QTcF ) interval great ( &gt; ) 450 msec ( male ) &gt; 470 msec ( female ) , history additional risk factor torsades de pointes . Participant history vasovagal episode . Participant history drug , alcohol , nicotine , caffeine abuse . Participant breastfeeding . Participant major surgery within 12 week Screening , donate 450 milliliter ( mL ) blood , acute loss equivalent amount blood within 90 day study drug administration . Participant positive fecal occult blood test result Screening . Participant history clinically significant drug and/or food allergy . Participant receive another investigational drug within 1 month period less 10 time drug 's halflife , whichever longer , plan first dose study drug Participant employee , family member employee , study site .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>58 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>JNJ-55375515</keyword>
	<keyword>Healthy</keyword>
	<keyword>Placebo</keyword>
</DOC>